Clinical Summary (HPI)
General Urology: 57 yM with Hx of elevated PSA presents today for path review. He is doing well s/p TP MRI fusion PNBx (04/2026) without ER visits or hospatalization. ----------------- Prior work-up: TP MRI fusion PNBx (04/2026): P3 lesion >1cm R PZPL at base. Path: Prostatic adenocarcinoma, Gleason 3+4=7 lesion 1B (100%) 1C (70%) 1A (60%), LPM#1 (90%), R PZ wing#1 (90%), RPL#1 (70%), RPM#1 (60%), LPM#2 (60%), RA#1 TZ (50%), RPM#2 (50%), R PZ wing#2 (20%), L A#1 TZ (20%). Gleason 3+3=6 LPL#2 (20%) (reviewed and interpreted) pMRI (01/2026): Prostate Vol 27g. PIRADS 3- Some focal decreased T2 signal noted R posterior bailar and mid gland peripheral zone, abuts prostatic capsule. PSAD 0.3 (reviewed and interpreted) UAmicro: Neg. UCx: Mixed flora (01/2026) Labs (11/2025): Chol 209, HDL 39, LDL 153, HbA1c 5.7, TSH 0.32, PSA (11/2025): 8.35.
Raw Note (de-identified preview)
4/21/26, 11:42 AM Print Preview
[PATIENT_NAME] DOB: [DOB] (57 yo M) Acc No. [ACCOUNT_ID] DOS: 04/20/2026
[PATIENT_NAME]
57 Y old Male, DOB: [DOB]
Account: [ACCOUNT_ID]: [PHONE] [ADDRESS], [ADDRESS]-[ZIP]
Home: [PHONE]
Guarantor: [GUARANTOR_NAME] Insurance: Aetna
PCP: [PROVIDER_NAME] Referring: [PROVIDER_NAME]
Appointment Facility: POTOMAC UROLOGY CENTER - Fair Oaks
04/20/2026 Prostate bx fu: [PROVIDER_NAME], MD
Reason for Appointment
1. Path review
History of Present Illness
General Urology:
57 yM with Hx of elevated PSA presents today for path review.
He is doing well s/p TP MRI fusion PNBx (04/2026) without ER visits or hospatalization.
-----------------
Prior work-up:
TP MRI fusion PNBx (04/2026): P3 lesion >1cm R PZPL at base. Path: Prostatic adenocarcinoma, Gleason
3+4=7 lesion 1B (100%) 1C (70%) 1A (60%), LPM#1 (90%), R PZ wing#1 (90%), RPL#1 (70%), RPM#1 (60%),
LPM#2 (60%), RA#1 TZ (50%), RPM#2 (50%), R PZ wing#2 (20%), L A#1 TZ (20%). Gleason 3+3=6 LPL#2
(20%) (reviewed and interpreted)
pMRI (01/2026): Prostate Vol 27g. PIRADS 3- Some focal decreased T2 signal noted R posterior bailar and mid gland
peripheral zone, abuts prostatic capsule. PSAD 0.3 (reviewed and interpreted)
UAmicro: Neg. UCx: Mixed flora (01/2026)
Labs (11/2025): Chol 209, HDL 39, LDL 153, HbA1c 5.7, TSH 0.32,
PSA (11/2025): 8.35.
Current Medications
Taking
Meloxicam 15 MG Tablet Oral
Concerta(Methylphenidate HCl ER (OSM)) 18 MG Tablet Extended Release 1 tablet in the morning Orally Once a day
FLUoxetine HCl 20 MG Capsule Oral
Not-Taking
PROzac 10 MG Capsule 1 capsule Orally Once a day , Notes to Pharmacist: 20 mg
Medication List reviewed and reconciled with the patient
Past Medical History
Anxiety.
Depression.
ADHD.
Elevated PSA.
High Cholesterol.
Obstructive Sleep Apnea (CPAP).
anxiety: Yes.
arthritis: Yes.
thyroid disease: Yes.
Progress Note: [PROVIDER_NAME], MD 04/20/2026
Note generated by eClinicalWorks EMR/PM Software (www.eClinicalWorks.com)
Generated for Printing/Faxing/eTransmitting on: 04/21/2026 02:42 PM EDT
1/3
4/21/26, 11:42 AM Print Preview
[PATIENT_NAME] DOB: [DOB] (57 yo M) Acc No. [ACCOUNT_ID] DOS: 04/20/2026
Surgical History
Prostate Bx 2026
Family History
Father: Cardiac
Social History
Recreational drug use: No.
Exercise: Yes.
Caffeine: Yes.
Alcohol Yes.
Sexually active: Yes.
Occupation: Yes.
Tobacco Control (Standard)
Tobacco use: Current smoker
Screening
Allergies
N.K.D.A.
Hospitalization/Major Diagnostic Procedure
No Hospitalization History.
Review of Systems
11 system Review of Systems completed in the chart and all pertinent positives and negatives reviewed with the
patient cdw.
Vital Signs
RR: 16, HR: 1, BP: 1 mm Hg, Ht: 66.5, Wt: 185 lbs, BMI: 29.41 Index.
Assessments
1.Prostate cancer - C61
Treatment
1.Prostate cancer
IMAGING: PET : PSMA Pylarify for Prostate Cancer
Notes:
PSA (11/2025): 8.35
pMRI (01/2026): Prostate Vol 27g. PIRADS 3- Some focal decreased T2 signal noted R posterior base and mid gland
peripheral zone, abuts prostatic capsule.